Although blood-based tau biomarkers have demonstrated high diagnostic performance, additional accessible biofluids may provide alternative molecular information and further support screening and disease monitoring strategies
47 DorostkarM
Stacking these effects may intensify GI side effects or mask early signs of medication intolerance, making it harder to distinguish which agent is responsible for any adverse event
10.1111/jpi.12422 179 YangJ.HuS.BianY.YaoJ.WangD.LiuX.et al (2021)
Drug PA, procedure PA, or full clinical
In the Phase 2 clinical trial published in The New England Journal of Medicine in 2023, gastrointestinal side effects affected the majority of participants, with nausea, vomiting, diarrhea, and constipation being the most frequent complaints